Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, Bagheri N, Meyfour A, Jafari A, Jahandideh S, Gharibi T, Amirkhani Z, Delam H, Mashatan N, Shahsavarani H, Abdollahpour-Alitappeh M.
Najminejad Z, et al. Among authors: jafari a.
Mol Ther. 2023 Jul 5;31(7):1874-1903. doi: 10.1016/j.ymthe.2023.03.019. Epub 2023 Mar 22.
Mol Ther. 2023.
PMID: 36950736
Free PMC article.
Review.